June 18, 2025 04:49 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Air India cancels Delhi-Paris flight too after nixing Ahmedabad-London journey | 'Can't allow mobs to take over streets, rule of law must prevail': Supreme Court slams ban on Kamal Haasan's Thug Life | Air India flight from Ahmedabad to London cancelled over unavailability of aircraft | How could Mamata Banerjee arrange alternate space so quickly?: Suvendu Adhikari cries conspiracy in Khidirpur market fire | Mumbai-bound Air India flight from San Francisco halted in Kolkata due to technical snag | Israel-Iran conflict: 110 Indian students evacuated to Armenia, to reach Delhi tomorrow | Everyone should immediately evacuate Tehran: Donald Trump as Israel-Iran conflict prevails | Khamenei appoints Major General Amir Hatami as new Iran Army chief after Israeli strikes killed top generals | Ahmedabad plane crash: Need to do extended surveillance into Boeing 787 Series, says Civil Aviation Minister | Ahmedabad plane crash: One more body recovered from debris
AstraZeneca | SII

AstraZeneca sends legal notice to Serum Institute over delays in vaccine supply

| @indiablooms | Apr 08, 2021, at 05:42 am

New Delhi/IBNS: Serum Institute of India (SII) has been served a legal notice by AstraZeneca over vaccine supply delays, a Business Standard report said.

According to the report, Adar Poonawalla, who is the CEO of Serum Institute of India, is trying to resolve the issue "amicably".

The restriction on Covishield exports and the first claim deal with India are difficult to explain to other countries where the shots are sold at much higher cost, he told Business Standard. 

Poonawalla said the SII has given 100 million doses to the Indian government and exported 60 million doses.

At its current capacity, the world's lagest vaccine manufacturer is producing 60 to 65 million doses per month.

Meanwhile, US ban on the exports of critical raw materials for vaccines has heightened the challenges in maintaining vaccine supply.

The ban imposed under US Defence Production Act is aimed at preserving raw materials for domestic manufacturer Merck & Co to produce Johnson & Johnson's COVID-19 vaccine, said a Reuters report.

SII is partnering with Novavax, an American vaccine development company, to manufacture another vaccine Covovax. Poonawalla has already said that ots launch is likely to be delayed to September in India.

In January SII had announced its launch in June.

US ban on raw materials will impact the production of Covovax by SII in India.

"From this month onwards, whatever we stockpile of Novavax would be half of what we could do, had it not been for US restrictions," Poonwalla said.

"This is as good as banning vaccines."

“This really needs to be looked at because if they are talking about building capacity all over the world, the sharing of these critical raw materials, which just can’t be replaced in a matter of six months or a year, is going to become a critical limiting factor,” he was quoted as saying in the Reutes report cited above.

SII has also sealed a deal to supply 200 million doses to COVID-19 Vaccines Global Access, abbreviated as Covax, an effort led by World Health Organization, UNICEF and others to procure and distribute vaccines to poor countries.

Earlier, UNICEF said that it anticipates that Serum Institute will be able to resume full deliveries of AstaZeneca vaccine in May.

 

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.